Trial Profile
A study evaluating the pharmacokinetics, safety, and tolerability of the bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) single tablet regimen (STR) in Japanese subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2017
Price :
$35
*
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 30 Aug 2017 New trial record
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science